PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A MONOTHERAPY OR IN COMBINATION WITH LAMIVUDINE COMPARED WITH UNTREATED CONTROL SUBJECTS IN CHILDREN WITH HBEAG-POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE-TOLERANT PHASE

Trial Profile

PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A MONOTHERAPY OR IN COMBINATION WITH LAMIVUDINE COMPARED WITH UNTREATED CONTROL SUBJECTS IN CHILDREN WITH HBEAG-POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE-TOLERANT PHASE

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 08 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top